Kapruvia® approved in Switzerland with additional

Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated...

Related Keywords

Australia ,Melbourne ,Victoria ,Canada ,United Kingdom ,Switzerland ,Singapore ,Christopher Posner ,Iris Francesconi ,Thomas Hutter ,Klaus Henning Jensen ,Annie Spinetta ,Instagram ,Linkedin ,Twitter ,Drug Administration ,International Journal Of Nephrology ,Nasdaq ,Regulatory Agency ,Exchange Commission ,Cara Therapeutics Inc ,Access Consortium ,National Registry Study ,European Medicines Agency ,Health Canada ,Swiss Agency For Therapeutic Products Swissmedic ,Fresenius Medical Care ,Fresenius Medical Care Renal Pharma ,Cara Therapeutics ,Swiss Agency ,Therapeutic Products ,United Kingdom Medicines ,Chief Medical Officer ,Chief Executive Officer ,New England Journal ,Vifor Fresenius Medical Care Renal Pharma ,Registry Study ,Private Securities Litigation Reform Act ,Quarterly Report ,Dialysis Outcomes ,Practice Patterns ,Nephrol Dial ,International Journal ,Patient Reported Outcomes ,Uremic Pruritus ,Clinj Am Soc ,Nasdaq Cara ,Nc ,